Oncology Business Management

The FDA has updated the label for abiraterone acetate plus prednisone to include significant overall survival data from the final analysis of the phase III COU-AA-302 study.

An sNDA for the full approval of carfilzomib (Kyprolis) as a treatment for patients with relapsed multiple myeloma has been granted a priority review by the FDA.

Patricia Hofstra, attorney, Duane Morris, discusses options that independent oncology groups have other than being acquired by larger healthcare or oncology systems.

A new report has called for broad changes in the way drugs are priced in the United States, saying the law of supply and demand is not doing an effective job of bringing the cost of cancer drugs down to a level comparable with other countries.

The FDA has approved dinutuximab in combination with interleukin-2, GM-CSF, and 13-cis-retinoic acid as a frontline therapy for pediatric patients with high-risk neuroblastoma.

The FDA has approved its first biosimilar, Zarxio, for all five its counterpart Neupogen's authorized indications.

Acting 3 months ahead of schedule, the FDA approved nivolumab (Odivo) for patients with squamous non-small cell lung cancer.

Rindopepimut (Rintega) has gained a Breakthrough Therapy Designation from the FDA to treat adult patients with glioblastoma multiforme that test positive for the epidermal growth factor receptor variant.

Oncologists, hematologists, and other experts on hematologic malignancies will convene for the 19th Annual International Congress on Hematologic Malignancies, from February 20-21 in Miami, Florida, to provide insight into recent developments in the treatment of the diseases.

The FDA has granted a priority review to the MEK inhibitor cobimetinib for use in combination with the BRAF inhibitor vemurafenib (Zelboraf) to treat patients with BRAF V600–positive advanced melanoma.

The FDA has approved lenalidomide (Revlimid) plus dexamethasone in newly diagnosed patients with multiple myeloma based on findings from the phase III FIRST trial.

OncLive and Tulane Cancer Center at the Tulane University School of Medicine have joined forces to promote awareness of new developments in cancer care through OncLive's Strategic Alliance Partnership program, OncLive announced today.

The COA has weighed in on a new system of higher value performance for oncologists, saying it is a step in the right direction but needs to be supported by broader reforms.

OncLive today welcomes Rutgers Cancer Institute of New Jersey as a partner in promoting awareness of the most recent advances in cancer care through OncLive's Strategic Alliance Partnership program

The only therapeutic cancer vaccine ever to win approval from the FDA has repeatedly missed sales projections, plunging the company that developed it into bankruptcy proceedings.

The American Board of Internal Medicine (ABIM) is making substantial changes to its Maintenance of Certification Program (MOC) for internists and subspecialists.

OncLive® welcomes the University of Chicago Medicine Comprehensive Cancer Center as a partner in raising the standard of cancer care through OncLive's Strategic Alliance Partnership program.

The FDA has expanded the approval of ibrutinib for the treatment of patients with Waldenström’s macroglobulinemia, according to a press release.